Skip to main content

Table 1 Patient characteristics

From: Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy

Variable

Value

Patients, n

31

Male/Female

14/17

Height, cm

65 (53-161)

Weight, kg

6.6 (3-57)

BSA, m2

0.46 ± 0.33

Age at study, months

7 (1-203)

Age < 4 weeks, n (%)

3 (10)

Age 1-24 months, n (%)

21 (68)

Age 2-12 years, n (%)

5 (16)

Age 12-18 years, n (%)

2 (6)

Cause of DCM

 

Unknown, n (%)

15 (48)

Chronic lymphocytic myocarditis, n (%)

16 (52)

Detection of virus by endomyocardial biopsy, n (%)

11 (35)

HHV6, n

6

PVB19, n

3

Enteroviruses, n

2

Blood testing

 

Troponin positive, n (%)

17 (55)

Tropnin, μg/l

0.18 ± 0.28

BNP, pg/ml

1900 ± 2019

NYHA-class, I/II/III/IV, n

0/2/13/16

Medication

ACE-I/ARB, n (%)

24 (77)

Beta-blocker, n (%)

24 (77)

Diuretics, n (%)

27 (87)

Digoxin, n (%)

13 (42)

Antiarrhytmic, n (%)

5 (16)

Inotropcis, n (%)

16 (52)

  1. DCM dilated cardiomyopathy, BSA Body surface area, PVB19 parvovirus B19, HHV6, human herpes virus type 6, BNP b-type natriuretic peptide, NYHA New York Heart Association, ACE-I angiotensin-converting inhibitors, ARB angiotensin receptor blocker; Data are presented as mean standard deviation (SD) or median and range, as appropriate